Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1126

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1126
---
 as add in vivo validation and drug
discovery to Lunai’s AI powered biomarker and diagnostic platform.

We trade on the NASDAQ Capital
Market under the ticker “RENB.”

Our website is http://www.renovarogroup.com.
We make available free of charge, on or through our website, our annual, quarterly, and current reports and any amendments to those reports
filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. Information contained in our website is not part of, nor incorporated by reference into, this report.

Item 1A. Risk Factors

RISK FACTORS

Risk Factor Summary

The following is a summary of the risks and uncertainties
that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk
factors contained in this report in their entirety for additional information regarding these risks and uncertainties. These risk factors
should be considered applicable across all subsidiaries.

    ●
    We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.

    ●
    There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.

    ●
    We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. Similarly, we have submitted multiple applications for non-dilutive (i.e., grant) funding from sources both in the US and Canada, and while we do not necessarily depend on the success of these applications to sustain operations, changing government policy may alter our capacity to obtain these grants, which may result in changes to company strategy.

18

    ●
    Raising additional capital may cause dilution to our existing stockholders or restrict our operations.

    ●
    From time to time, we may be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management’s attention, and materially harm our business, financial condition, and operating results.

    ●
    Negative publicity has had and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners and collaborators.

    ●
    Lunai Bioworks is a pre